Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Facephi, experts in digital identity and fraud prevention in regulated environments, provides a Regulatory Compliance Pocket Guide for the financial sector
-
Facephi and Huenei Forge Strategic Alliance to Strengthen Digital Identity Solutions in Latin America and the United States Huenei IT Services is a software developer with 30+ years in Latin America,...
-
AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- SEON, the command center for real-time Fraud Prevention and AML Compliance, today released AI Reality Check: 2026 Fraud & AML Leaders Report, the...
-
Dublin, Feb. 10, 2026 (GLOBE NEWSWIRE) -- The "Conduct Risk (February 15, 2026)" training has been added to ResearchAndMarkets.com's offering. Conduct risk is a key challenge to many financial...
-
AUSTIN, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SEON, the command center for real-time fraud prevention and AML compliance, delivered over 80% ARR growth in 2025 and added hundreds of new customers...
-
Facephi Ranks No. 1 in Biometric & Document Authentication Capabilities in the Identity Platform Category by The Prism Project #1 in Biometric & Document Authentication Capabilities within...
-
AUSTIN, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- SEON, the command center for real-time fraud prevention and AML compliance, has earned three AWS (Amazon Web Services) Competencies based on proven...
-
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia AMX-883-induced BRD9...
-
FOR IMMEDIATE RELEASE -- ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025 -- Updated clinical data presented at ASH show robust efficacy,...
-
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted...